Released May 5, 2022, after the close
10-Q filed May 9, 2022, 39 days after period end · 0001162194-22-000055
Q1 2022 · 10-Q
Revenue$26.50M$26.50M −19.2% vs Q1 2021−30.7% vs Q4 2021
Net Income-$76.29M-$76.29M N/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.99-$0.99 N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$27,503,000N/M
Operating Cash Flow-$15,590,000N/M
Free Cash Flowderived-$16,458,000N/M
Margins · derived
Operating margin-103.8%−44.9 pt vs Q1 2021
Net margin-287.8%−230.4 pt vs Q1 2021
What the release said
The release
Same quarter
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Revenue | $26.50M | $32.79M | $27.62M | $30.11M |
| Net Income | -$76.29M | -$18.82M | -$15.98M | -$25.47M |
| EPS Diluted | -$0.99 | -$0.25 | -$0.23 | -$0.44 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR